Clostridium difficile Infection in the Elderly

Clinics in Geriatric Medicine

Volumn 30, Issue 1, 2014, Pages 79-93

  Keller, Jonathan M ^a   Surawicz, Christina M ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antibiotic associated diarrhea; Clostridium difficile; Elderly

Indexed keywords

ANTITOXIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; METRONIDAZOLE; PROBIOTIC AGENT; TOXOID; VANCOMYCIN;

AGE DISTRIBUTION; ALGORITHM; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; BACTERIUM DETECTION; CHEMOPROPHYLAXIS; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG DOSE INCREASE; DRUG MEGADOSE; EARLY DIAGNOSIS; ENVIRONMENTAL EXPOSURE; ENZYME IMMUNOASSAY; FECES MICROFLORA; GERIATRIC PATIENT; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IMMUNIZATION; INCIDENCE; LENGTH OF STAY; LONG TERM CARE; NASOGASTRIC DRUG ADMINISTRATION; NONHUMAN; NUCLEIC ACID AMPLIFICATION; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; RISK FACTOR; TISSUE CULTURE; TOXIN ANALYSIS; TREATMENT DURATION;

ANTIBIOTIC-ASSOCIATED DIARRHEA; CLOSTRIDIUM DIFFICILE; ELDERLY;

AGED; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; DISEASE MANAGEMENT; HUMANS; METRONIDAZOLE; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VANCOMYCIN;

EID: 84888146253     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2013.10.008     Document Type: Review

References (90)

1. Bartlett J.G. Clinical practice. Antibiotic-associated diarrhea. NEngl J Med 2002, 346:334-339.
2. Thielman N.M., Guerrant R.L. Clinical practice. Acute infectious diarrhea. NEngl J Med 2004, 350:38-47.
3. Miller B.A., Chen L.F., Sexton D.J., et al. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011, 32:387-390.
4. Laffan A.M., Bellantoni M.F., Greenough W.B., et al. Burden of Clostridium difficile-associated diarrhea in a long-term care facility. JAm Geriatr Soc 2006, 54:1068-1073.
5. Bartlett J.G. Antibiotic-associated diarrhea. Clin Infect Dis 1992, 15:573-581.
6. Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays. Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality Statistical Brief #124 2009.
7. McGlone S.M., Bailey R.R., Zimmer S.M., et al. The economic burden of Clostridium difficile. Clin Microbiol Infect 2012, 18:282-289.
8. Loo V.G., Poirier L., Miller M.A., et al. Apredominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. NEngl J Med 2005, 353:2442-2449.
9. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. NEngl J Med 2005, 353:2433-2441.
10. Clements A.C., Magalhães R.J., Tatem A.J., et al. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010, 10:395-404.
11. Gerding D.N. Clostridium difficile 30 years on: what has, or has not, changed and why?. Int J Antimicrob Agents 2009, 33(Suppl 1):S2-S8.
12. Miniño A.M., Murphy S.L., Xu J., et al. Deaths: final data for 2008. Natl Vital Stat Rep 2011, 59:1-126.
13. Kyne L., Hamel M.B., Polavaram R., et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002, 34:346-353.
14. Kelly C.P., Pothoulakis C., LaMont J.T. Clostridium difficile colitis. NEngl J Med 1994, 330:257-262.
15. Bartlett J.G., Chang T.W., Gurwith M., et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. NEngl J Med 1978, 298:531-534.
16. Manges A.R., Labbe A., Loo V.G., et al. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. JInfect Dis 2010, 202:1877-1884.
17. Thelestam M., Chaves-Olarte E. Cytotoxic effects of the Clostridium difficile toxins. Curr Top Microbiol Immunol 2000, 250:85-96.
18. McFarland L.V., Mulligan M.E., Kwok R.Y., et al. Nosocomial acquisition of Clostridium difficile infection. NEngl J Med 1989, 320:204-210.
19. Kyne L., Warny M., Qamar A., et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357:189-193.
20. Kyne L., Warny M., Qamar A., et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. NEngl J Med 2000, 342:390-397.
21. Frasca D., Diaz A., Romero M., et al. Age effects on B cells and humoral immunity in humans. Ageing Res Rev 2011, 10:330-335.
22. Surawicz C.M., Brandt L.J., Binion D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013, 108:478-498. [quiz: 499].
23. Kim J.H., Muder R.R. Clostridium difficile enteritis: a review and pooled analysis of the cases. Anaerobe 2011, 17:52-55.
24. McDonald L.C., Owings M., Jernigan D.B. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006, 12:409-415.
25. Loo V.G., Bourgault A.M., Poirier L., et al. Host and pathogen factors for Clostridium difficile infection and colonization. NEngl J Med 2011, 365:1693-1703.
26. Hopkins M.J., Macfarlane G.T. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. JMed Microbiol 2002, 51:448-454.
27. Rea M.C., O'Sullivan O., Shanahan F., et al. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. JClin Microbiol 2012, 50:867-875.
28. Skraban J., Dzeroski S., Zenko B., et al. Gut microbiota patterns associated with colonization of different Clostridium difficile ribotypes. PloS One 2013, 8:e58005.
29. Hakim F.T., Gress R.E. Immunosenescence: deficits in adaptive immunity in the elderly. Tissue Antigens 2007, 70:179-189.
30. Ginaldi L., Loreto M.F., Corsi M.P., et al. Immunosenescence and infectious diseases. Microbes Infect 2001, 3:851-857.
31. Warny M., Vaerman J.P., Avesani V., et al. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994, 62:384-389.
32. Solomon K., Martin A.J., O'Donoghue C., et al. Mortality in patients with Clostridium difficile infection correlates with host pro-inflammatory and humoral immune responses. JMed Microbiol 2013, 62:1453-1460.
33. Freeman J., Wilcox M.H. Antibiotics and Clostridium difficile. Microbes Infect 1999, 1:377-384.
34. Freeman J., Bauer M.P., Baines S.D., et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010, 23:529-549.
35. Hensgens M.P., Goorhuis A., Dekkers O.M., et al. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. JAntimicrob Chemother 2012, 67:742-748.
36. Stevens V., Dumyati G., Fine L.S., et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011, 53:42-48.
37. Srinivasan A., Fishman N. Antimicrobial stewardship 2012: science driving practice. Infect Control Hosp Epidemiol 2012, 33:319-321.
38. Jacob J.T., Gaynes R.P. Emerging trends in antibiotic use in US hospitals: quality, quantification and stewardship. Expert Rev Anti Infect Ther 2010, 8:893-902.
39. Khanna S., Pardi D.S., Aronson S.L., et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2012, 107:89-95.
40. Weber D.J., Anderson D.J., Sexton D.J., et al. Role of the environment in the transmission of Clostridium difficile in health care facilities. Am J Infect Control 2013, 41:S105-S110.
41. Salkind A.R. Clostridium difficile: an update for the primary care clinician. South Med J 2010, 103:896-902.
42. Bartlett J.G. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S4-S11.
43. Riggs M.M., Sethi A.K., Zabarsky T.F., et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007, 45:992-998.
44. Guerrero D.M., Becker J.C., Eckstein E.C., et al. Asymptomatic carriage of toxigenic Clostridium difficile by hospitalized patients. JHosp Infect 2013, 85:155-158.
45. Yakob L., Riley T.V., Paterson D.L., et al. Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model. BMC Infect Dis 2013, 13:376.
46. Shaughnessy M.K., Micielli R.L., DePestel D.D., et al. Evaluation of hospital room assignment and acquisition of Clostridium difficile infection. Infect Control Hosp Epidemiol 2011, 32:201-206.
47. Kim J.H., Toy D., Muder R.R. Clostridium difficile infection in a long-term care facility: hospital-associated illness compared with long-term care-associated illness. Infect Control Hosp Epidemiol 2011, 32:656-660.
48. Campbell R.J., Giljahn L., Machesky K., et al. Clostridium difficile infection in Ohio hospitals and nursing homes during 2006. Infect Control Hosp Epidemiol 2009, 30:526-533.
49. Mylotte J.M., Russell S., Sackett B., et al. Surveillance for Clostridium difficile infection in nursing homes. JAm Geriatr Soc 2013, 61:122-125.
50. Berg A.M., Kelly C.P., Farraye F.A. Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm Bowel Dis 2013, 19:194-204.
51. Neofytos D., Kobayashi K., Alonso C.D., et al. Epidemiology, risk factors, and outcomes of Clostridium difficile infection in kidney transplant recipients. Transpl Infect Dis 2013, 15:134-141.
52. Alonso C.D., Dufresne S.F., Hanna D.B., et al. Clostridium difficile infection after adult autologous stem cell transplantation: a multicenter study of epidemiology and risk factors. Biol Blood Marrow Transplant 2013, 19:1502-1508.
53. O'Keefe S.J. Tube feeding, the microbiota, and Clostridium difficile infection. World J Gastroenterol 2010, 16:139-142.
54. Bunchorntavakul C., Chavalitdhamrong D. Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. World J Hepatol 2012, 4:158-168.
55. Eddi R., Malik M.N., Shakov R., et al. Chronic kidney disease as a risk factor for Clostridium difficile infection. Nephrology (Carlton) 2010, 15:471-475.
56. Southern W.N., Rahmani R., Aroniadis O., et al. Postoperative Clostridium difficile-associated diarrhea. Surgery 2010, 148:24-30.
57. Thorens J., Froehlich F., Schwizer W., et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996, 39:54-59.
58. Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol 2001, 15:511-521.
59. Kwok C.S., Arthur A.K., Anibueze C.I., et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012, 107:1011-1019.
60. Choudhry M.N., Soran H., Ziglam H.M. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM 2008, 101:445-448.
61. Dalton B.R., Lye-Maccannell T., Henderson E.A., et al. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Aliment Pharmacol Ther 2009, 29:626-634.
62. Rogers M.A., Greene M.T., Young V.B., et al. Depression, antidepressant medications, and risk of Clostridium difficile infection. BMC Med 2013, 11:121.
63. Naggie S., Miller B.A., Zuzak K.B., et al. Acase-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med 2011, 124:276.e1-276.e7.
64. Motzkus-Feagans C.A., Pakyz A., Polk R., et al. Statin use and the risk of Clostridium difficile in academic medical centres. Gut 2012, 61:1538-1542.
65. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
66. Gough E., Shaikh H., Manges A.R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011, 53:994-1002.
67. Brandt L.J., Aroniadis O.C., Mellow M., et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012, 107:1079-1087.
68. Burke K.E., Lamont J.T. Fecal transplantation for recurrent Clostridium difficile infection in older adults: a review. JAm Geriatr Soc 2013, 61:1394-1398.
69. Lowy I., Molrine D.C., Leav B.A., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. NEngl J Med 2010, 362:197-205.
70. Goldenberg J.Z., Ma S.S., Saxton J.D., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013, (5). CD006095.
71. Allen S., Wareham K., Wang D., et al. PWE-008 placide: probiotics in the prevention of antibiotic associated diarrhoea (AAD) and Clostridium difficile associated diarrhoea (CDD) in elderly patients admitted to hospital: results of a large multi-centre RCT in the UK. Gut 2013, 62:A133.
72. Salminen M.K., Tynkkynen S., Rautelin H., et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002, 35:1155-1160.
73. Salminen M.K., Rautelin H., Tynkkynen S., et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004, 38:62-69.
74. Kotloff K.L., Wasserman S.S., Losonsky G.A., et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001, 69:988-995.
75. Dorrington M.G., Bowdish D.M. Immunosenescence and novel vaccination strategies for the elderly. Front Immunol 2013, 4:171.
76. Greenberg R.N., Marbury T.C., Foglia G., et al. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 2012, 30:2245-2249.
77. Johnson S., Homann S.R., Bettin K.M., et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992, 117:297-302.
78. Chang H.T., Krezolek D., Johnson S., et al. Onset of symptoms and time to diagnosis of Clostridium difficile-associated disease following discharge from an acute care hospital. Infect Control Hosp Epidemiol 2007, 28:926-931.
79. Russell A.D. Bacterial spores and chemical sporicidal agents. Clin Microbiol Rev 1990, 3:99-119.
80. Kim K.H., Fekety R., Batts D.H., et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. JInfect Dis 1981, 143:42-50.
81. Boyce J.M., Pittet D. Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002, 51:1-45. [quiz: CE1-4].
82. Sethi A.K., Al-Nassir W.N., Nerandzic M.M., et al. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidemiol 2010, 31:21-27.
83. Simor A.E., Williams V., McGeer A., et al. Prevalence of colonization and infection with methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus and of Clostridium difficile infection in Canadian hospitals. Infect Control Hosp Epidemiol 2013, 34:687-693.
84. Jones A.L., Dwyer L.L., Bercovitz A.R., et al. The National Nursing Home Survey: 2004 overview. Vital Health Stat 13 2009, (167):1-155.
85. Dubberke E.R., Olsen M.A. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012, 55(Suppl 2):S88-S92.
86. Nicolle L.E., Bentley D.W., Garibaldi R., et al. Antimicrobial use in long-term-care facilities. SHEA Long-Term-Care Committee. Infect Control Hosp Epidemiol 2000, 21:537-545.
87. Jump R.L., Olds D.M., Seifi N., et al. Effective antimicrobial stewardship in a long-term care facility through an infectious disease consultation service: keeping a LID on antibiotic use. Infect Control Hosp Epidemiol 2012, 33:1185-1192.
88. Davey P., Brown E., Fenelon L., et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis 2006, 12:211-216.
89. Aldeyab M.A., Kearney M.P., Scott M.G., et al. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. JAntimicrob Chemother 2012, 67:2988-2996.
90. Davey P., Brown E., Fenelon L., et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2005, (4). CD003543.